The Multimodal Serotonergic Agent Vilazodone Inhibits L-DOPA-Induced Gene Regulation in Striatal Projection Neurons and Associated Dyskinesia in an Animal Model of Parkinson’s Disease
Levodopa (L-DOPA) treatment in Parkinson’s disease is limited by the emergence of L-DOPA-induced dyskinesia. Such dyskinesia is associated with aberrant gene regulation in neurons of the striatum, which is caused by abnormal dopamine release from serotonin terminals. Previous work showed that modula...
Main Authors: | Feras Altwal, Connor Moon, Anthony R. West, Heinz Steiner |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-10-01
|
Series: | Cells |
Subjects: | |
Online Access: | https://www.mdpi.com/2073-4409/9/10/2265 |
Similar Items
-
Role of 5-HT1A Receptor in Vilazodone-Mediated Suppression of L-DOPA-Induced Dyskinesia and Increased Responsiveness to Cortical Input in Striatal Medium Spiny Neurons in an Animal Model of Parkinson’s Disease
by: Feras Altwal, et al.
Published: (2021-09-01) -
5-Hydroxy-tryptophan for the treatment of l-DOPA-induced dyskinesia in the rat Parkinson's disease model
by: Elisabetta Tronci, et al.
Published: (2013-12-01) -
Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson's disease
by: Sylvia Navailles, et al.
Published: (2010-04-01) -
Serotonin system implication in L-DOPA-induced dyskinesia: from animal models to clinical investigations
by: Manolo eCarta, et al.
Published: (2014-05-01) -
Chronic L-DOPA therapy alters central serotonergic function and L-DOPA-induced dopamine release in a region-dependent manner in a rat model of Parkinson's disease
by: Sylvia Navailles, et al.
Published: (2011-02-01)